Src inhibitors in lung cancer: current status and future directions

Rothschild, Sacha I; Gautschi, Oliver; Haura, Eric B; Johnson, Faye M (2010). Src inhibitors in lung cancer: current status and future directions. Clinical lung cancer, 11(4), pp. 238-42. New York, N.Y.: Elsevier 10.3816/CLC.2010.n.030

Full text not available from this repository.

Src tyrosine kinases regulate multiple genetic and signaling pathways involved in the proliferation, survival, angiogenesis, invasion, and migration of various types of cancer cells They are frequently expressed and activated in many cancer types, including lung cancer. Several Src inhibitors, including dasatinib, saracatinib, bosutinib, and KX2-391, are currently being investigated in clinical trials. Preliminary results of the use of single-agent Src inhibitors in unselected patients with lung cancer show that these inhibitors have a favorable safety profile and anticancer activity. Their combination with cytotoxic chemotherapy, other targeted therapy, and radiation therapy is currently being explored. In this review, we summarize the rationale for and the current status of Src inhibitor development and discuss future directions based on emerging preclinical data.

Item Type:	Journal Article (Further Contribution)
Division/Institute:	04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology
UniBE Contributor:	Gautschi, Oliver
ISSN:	1525-7304
Publisher:	Elsevier
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 14:09
Last Modified:	05 Dec 2022 14:00
Publisher DOI:	10.3816/CLC.2010.n.030
PubMed ID:	20630825
Web of Science ID:	000279496400004
URI:	https://boris.unibe.ch/id/eprint/1190 (FactScience: 202214)